NO302156B1 - Fremgangsmåte for fremstilling av et transdermalt farmasöytisk system - Google Patents
Fremgangsmåte for fremstilling av et transdermalt farmasöytisk system Download PDFInfo
- Publication number
- NO302156B1 NO302156B1 NO912985A NO912985A NO302156B1 NO 302156 B1 NO302156 B1 NO 302156B1 NO 912985 A NO912985 A NO 912985A NO 912985 A NO912985 A NO 912985A NO 302156 B1 NO302156 B1 NO 302156B1
- Authority
- NO
- Norway
- Prior art keywords
- skin
- active substance
- value
- active ingredient
- additive material
- Prior art date
Links
- 238000000034 method Methods 0.000 title claims description 9
- 238000002360 preparation method Methods 0.000 title description 4
- 230000008569 process Effects 0.000 title description 2
- 239000013543 active substance Substances 0.000 claims description 32
- 239000000463 material Substances 0.000 claims description 20
- 239000000654 additive Substances 0.000 claims description 19
- 229920000642 polymer Polymers 0.000 claims description 17
- 239000011159 matrix material Substances 0.000 claims description 15
- 230000000996 additive effect Effects 0.000 claims description 14
- STJMRWALKKWQGH-UHFFFAOYSA-N clenbuterol Chemical group CC(C)(C)NCC(O)C1=CC(Cl)=C(N)C(Cl)=C1 STJMRWALKKWQGH-UHFFFAOYSA-N 0.000 claims description 14
- 239000010410 layer Substances 0.000 claims description 14
- 229960001117 clenbuterol Drugs 0.000 claims description 13
- 239000004480 active ingredient Substances 0.000 claims description 11
- 239000000203 mixture Substances 0.000 claims description 10
- 239000000872 buffer Substances 0.000 claims description 9
- 238000004519 manufacturing process Methods 0.000 claims description 9
- 229920000058 polyacrylate Polymers 0.000 claims description 7
- 239000002253 acid Substances 0.000 claims description 6
- 239000012528 membrane Substances 0.000 claims description 6
- 239000012790 adhesive layer Substances 0.000 claims description 4
- 239000007853 buffer solution Substances 0.000 claims description 4
- 230000001225 therapeutic effect Effects 0.000 claims description 4
- 239000007933 dermal patch Substances 0.000 claims description 2
- 229910017053 inorganic salt Inorganic materials 0.000 claims description 2
- 239000003960 organic solvent Substances 0.000 claims description 2
- 238000001704 evaporation Methods 0.000 claims 1
- 150000001875 compounds Chemical class 0.000 abstract description 2
- 210000003491 skin Anatomy 0.000 description 42
- 239000000243 solution Substances 0.000 description 13
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 12
- 239000002245 particle Substances 0.000 description 8
- 230000002378 acidificating effect Effects 0.000 description 7
- 239000011888 foil Substances 0.000 description 5
- 239000011505 plaster Substances 0.000 description 5
- 150000003839 salts Chemical class 0.000 description 5
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 4
- 239000004908 Emulsion polymer Substances 0.000 description 4
- 235000015165 citric acid Nutrition 0.000 description 4
- 239000000839 emulsion Substances 0.000 description 4
- 239000002904 solvent Substances 0.000 description 4
- 238000003756 stirring Methods 0.000 description 4
- 239000000126 substance Substances 0.000 description 4
- 229940100640 transdermal system Drugs 0.000 description 4
- 150000007513 acids Chemical class 0.000 description 3
- 230000001580 bacterial effect Effects 0.000 description 3
- 230000008901 benefit Effects 0.000 description 3
- 229920001577 copolymer Polymers 0.000 description 3
- 229940079593 drug Drugs 0.000 description 3
- 239000003814 drug Substances 0.000 description 3
- 239000011521 glass Substances 0.000 description 3
- 230000035699 permeability Effects 0.000 description 3
- -1 polybutadene Polymers 0.000 description 3
- 230000001681 protective effect Effects 0.000 description 3
- 239000011877 solvent mixture Substances 0.000 description 3
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 3
- KWGRBVOPPLSCSI-WPRPVWTQSA-N (-)-ephedrine Chemical compound CN[C@@H](C)[C@H](O)C1=CC=CC=C1 KWGRBVOPPLSCSI-WPRPVWTQSA-N 0.000 description 2
- SMZOUWXMTYCWNB-UHFFFAOYSA-N 2-(2-methoxy-5-methylphenyl)ethanamine Chemical compound COC1=CC=C(C)C=C1CCN SMZOUWXMTYCWNB-UHFFFAOYSA-N 0.000 description 2
- 102000002723 Atrial Natriuretic Factor Human genes 0.000 description 2
- 101800001288 Atrial natriuretic factor Proteins 0.000 description 2
- 101800001890 Atrial natriuretic peptide Proteins 0.000 description 2
- 229920003163 Eudragit® NE 30 D Polymers 0.000 description 2
- CERQOIWHTDAKMF-UHFFFAOYSA-N Methacrylic acid Chemical compound CC(=C)C(O)=O CERQOIWHTDAKMF-UHFFFAOYSA-N 0.000 description 2
- DFPAKSUCGFBDDF-UHFFFAOYSA-N Nicotinamide Chemical compound NC(=O)C1=CC=CN=C1 DFPAKSUCGFBDDF-UHFFFAOYSA-N 0.000 description 2
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical compound [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 description 2
- UIIMBOGNXHQVGW-UHFFFAOYSA-M Sodium bicarbonate Chemical compound [Na+].OC([O-])=O UIIMBOGNXHQVGW-UHFFFAOYSA-M 0.000 description 2
- 239000000853 adhesive Substances 0.000 description 2
- 230000001070 adhesive effect Effects 0.000 description 2
- 239000008280 blood Substances 0.000 description 2
- 210000004369 blood Anatomy 0.000 description 2
- 238000009835 boiling Methods 0.000 description 2
- NSQLIUXCMFBZME-MPVJKSABSA-N carperitide Chemical compound C([C@H]1C(=O)NCC(=O)NCC(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CC(O)=O)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@H](C(NCC(=O)N[C@@H](C)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CO)C(=O)NCC(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](CSSC[C@@H](C(=O)N1)NC(=O)[C@H](CO)NC(=O)[C@H](CO)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CCCNC(N)=N)NC(=O)[C@H](CC(C)C)NC(=O)[C@@H](N)CO)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CO)C(=O)N[C@@H](CC=1C=CC=CC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C=CC(O)=CC=1)C(O)=O)=O)[C@@H](C)CC)C1=CC=CC=C1 NSQLIUXCMFBZME-MPVJKSABSA-N 0.000 description 2
- 238000001342 constant potential amperometry Methods 0.000 description 2
- 230000001276 controlling effect Effects 0.000 description 2
- 238000001816 cooling Methods 0.000 description 2
- 230000007423 decrease Effects 0.000 description 2
- 238000009792 diffusion process Methods 0.000 description 2
- ZPWVASYFFYYZEW-UHFFFAOYSA-L dipotassium hydrogen phosphate Chemical compound [K+].[K+].OP([O-])([O-])=O ZPWVASYFFYYZEW-UHFFFAOYSA-L 0.000 description 2
- 238000001035 drying Methods 0.000 description 2
- 238000007720 emulsion polymerization reaction Methods 0.000 description 2
- 239000000499 gel Substances 0.000 description 2
- 238000010438 heat treatment Methods 0.000 description 2
- 229930195733 hydrocarbon Natural products 0.000 description 2
- NOESYZHRGYRDHS-UHFFFAOYSA-N insulin Chemical compound N1C(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(NC(=O)CN)C(C)CC)CSSCC(C(NC(CO)C(=O)NC(CC(C)C)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CCC(N)=O)C(=O)NC(CC(C)C)C(=O)NC(CCC(O)=O)C(=O)NC(CC(N)=O)C(=O)NC(CC=2C=CC(O)=CC=2)C(=O)NC(CSSCC(NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2C=CC(O)=CC=2)NC(=O)C(CC(C)C)NC(=O)C(C)NC(=O)C(CCC(O)=O)NC(=O)C(C(C)C)NC(=O)C(CC(C)C)NC(=O)C(CC=2NC=NC=2)NC(=O)C(CO)NC(=O)CNC2=O)C(=O)NCC(=O)NC(CCC(O)=O)C(=O)NC(CCCNC(N)=N)C(=O)NCC(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC=CC=3)C(=O)NC(CC=3C=CC(O)=CC=3)C(=O)NC(C(C)O)C(=O)N3C(CCC3)C(=O)NC(CCCCN)C(=O)NC(C)C(O)=O)C(=O)NC(CC(N)=O)C(O)=O)=O)NC(=O)C(C(C)CC)NC(=O)C(CO)NC(=O)C(C(C)O)NC(=O)C1CSSCC2NC(=O)C(CC(C)C)NC(=O)C(NC(=O)C(CCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(NC(=O)C(N)CC=1C=CC=CC=1)C(C)C)CC1=CN=CN1 NOESYZHRGYRDHS-UHFFFAOYSA-N 0.000 description 2
- 239000003791 organic solvent mixture Substances 0.000 description 2
- 229920000193 polymethacrylate Polymers 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 description 2
- 210000000434 stratum corneum Anatomy 0.000 description 2
- XWTYSIMOBUGWOL-UHFFFAOYSA-N (+-)-Terbutaline Chemical compound CC(C)(C)NCC(O)C1=CC(O)=CC(O)=C1 XWTYSIMOBUGWOL-UHFFFAOYSA-N 0.000 description 1
- GJSURZIOUXUGAL-UHFFFAOYSA-N Clonidine Chemical compound ClC1=CC=CC(Cl)=C1NC1=NCCN1 GJSURZIOUXUGAL-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- 229920003134 Eudragit® polymer Polymers 0.000 description 1
- 241000282412 Homo Species 0.000 description 1
- DGAQECJNVWCQMB-PUAWFVPOSA-M Ilexoside XXIX Chemical compound C[C@@H]1CC[C@@]2(CC[C@@]3(C(=CC[C@H]4[C@]3(CC[C@@H]5[C@@]4(CC[C@@H](C5(C)C)OS(=O)(=O)[O-])C)C)[C@@H]2[C@]1(C)O)C)C(=O)O[C@H]6[C@@H]([C@H]([C@@H]([C@H](O6)CO)O)O)O.[Na+] DGAQECJNVWCQMB-PUAWFVPOSA-M 0.000 description 1
- 238000012404 In vitro experiment Methods 0.000 description 1
- 102000004877 Insulin Human genes 0.000 description 1
- 108090001061 Insulin Proteins 0.000 description 1
- VVQNEPGJFQJSBK-UHFFFAOYSA-N Methyl methacrylate Chemical compound COC(=O)C(C)=C VVQNEPGJFQJSBK-UHFFFAOYSA-N 0.000 description 1
- SNIOPGDIGTZGOP-UHFFFAOYSA-N Nitroglycerin Chemical compound [O-][N+](=O)OCC(O[N+]([O-])=O)CO[N+]([O-])=O SNIOPGDIGTZGOP-UHFFFAOYSA-N 0.000 description 1
- 239000000006 Nitroglycerin Substances 0.000 description 1
- PIJVFDBKTWXHHD-UHFFFAOYSA-N Physostigmine Natural products C12=CC(OC(=O)NC)=CC=C2N(C)C2C1(C)CCN2C PIJVFDBKTWXHHD-UHFFFAOYSA-N 0.000 description 1
- 239000004793 Polystyrene Substances 0.000 description 1
- ZLMJMSJWJFRBEC-UHFFFAOYSA-N Potassium Chemical compound [K] ZLMJMSJWJFRBEC-UHFFFAOYSA-N 0.000 description 1
- BKRGVLQUQGGVSM-KBXCAEBGSA-N Revanil Chemical compound C1=CC(C=2[C@H](N(C)C[C@H](C=2)NC(=O)N(CC)CC)C2)=C3C2=CNC3=C1 BKRGVLQUQGGVSM-KBXCAEBGSA-N 0.000 description 1
- 206010040880 Skin irritation Diseases 0.000 description 1
- VMHLLURERBWHNL-UHFFFAOYSA-M Sodium acetate Chemical compound [Na+].CC([O-])=O VMHLLURERBWHNL-UHFFFAOYSA-M 0.000 description 1
- 239000000150 Sympathomimetic Substances 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- GXBMIBRIOWHPDT-UHFFFAOYSA-N Vasopressin Natural products N1C(=O)C(CC=2C=C(O)C=CC=2)NC(=O)C(N)CSSCC(C(=O)N2C(CCC2)C(=O)NC(CCCN=C(N)N)C(=O)NCC(N)=O)NC(=O)C(CC(N)=O)NC(=O)C(CCC(N)=O)NC(=O)C1CC1=CC=CC=C1 GXBMIBRIOWHPDT-UHFFFAOYSA-N 0.000 description 1
- 108010004977 Vasopressins Proteins 0.000 description 1
- 102000002852 Vasopressins Human genes 0.000 description 1
- 150000008043 acidic salts Chemical class 0.000 description 1
- 239000011543 agarose gel Substances 0.000 description 1
- NDAUXUAQIAJITI-UHFFFAOYSA-N albuterol Chemical compound CC(C)(C)NCC(O)C1=CC=C(O)C(CO)=C1 NDAUXUAQIAJITI-UHFFFAOYSA-N 0.000 description 1
- 125000005907 alkyl ester group Chemical group 0.000 description 1
- KBZOIRJILGZLEJ-LGYYRGKSSA-N argipressin Chemical compound C([C@H]1C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC(N)=O)C(=O)N[C@@H](CSSC[C@@H](C(N[C@@H](CC=2C=CC(O)=CC=2)C(=O)N1)=O)N)C(=O)N1[C@@H](CCC1)C(=O)N[C@@H](CCCN=C(N)N)C(=O)NCC(N)=O)C1=CC=CC=C1 KBZOIRJILGZLEJ-LGYYRGKSSA-N 0.000 description 1
- 208000006673 asthma Diseases 0.000 description 1
- 208000002352 blister Diseases 0.000 description 1
- 229910021538 borax Inorganic materials 0.000 description 1
- KGBXLFKZBHKPEV-UHFFFAOYSA-N boric acid Chemical compound OB(O)O KGBXLFKZBHKPEV-UHFFFAOYSA-N 0.000 description 1
- 239000004327 boric acid Substances 0.000 description 1
- 235000010338 boric acid Nutrition 0.000 description 1
- YYRMJZQKEFZXMX-UHFFFAOYSA-L calcium bis(dihydrogenphosphate) Chemical compound [Ca+2].OP(O)([O-])=O.OP(O)([O-])=O YYRMJZQKEFZXMX-UHFFFAOYSA-L 0.000 description 1
- 229910000389 calcium phosphate Inorganic materials 0.000 description 1
- 239000012876 carrier material Substances 0.000 description 1
- 230000008859 change Effects 0.000 description 1
- 238000006243 chemical reaction Methods 0.000 description 1
- 229960002896 clonidine Drugs 0.000 description 1
- 239000011248 coating agent Substances 0.000 description 1
- 238000000576 coating method Methods 0.000 description 1
- KWGRBVOPPLSCSI-UHFFFAOYSA-N d-ephedrine Natural products CNC(C)C(O)C1=CC=CC=C1 KWGRBVOPPLSCSI-UHFFFAOYSA-N 0.000 description 1
- 235000019797 dipotassium phosphate Nutrition 0.000 description 1
- 229910000396 dipotassium phosphate Inorganic materials 0.000 description 1
- BNIILDVGGAEEIG-UHFFFAOYSA-L disodium hydrogen phosphate Chemical compound [Na+].[Na+].OP([O-])([O-])=O BNIILDVGGAEEIG-UHFFFAOYSA-L 0.000 description 1
- 229960002179 ephedrine Drugs 0.000 description 1
- 210000002615 epidermis Anatomy 0.000 description 1
- 150000002148 esters Chemical class 0.000 description 1
- 150000002170 ethers Chemical class 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 230000002349 favourable effect Effects 0.000 description 1
- 229960002428 fentanyl Drugs 0.000 description 1
- IVLVTNPOHDFFCJ-UHFFFAOYSA-N fentanyl citrate Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O.C=1C=CC=CC=1N(C(=O)CC)C(CC1)CCN1CCC1=CC=CC=C1 IVLVTNPOHDFFCJ-UHFFFAOYSA-N 0.000 description 1
- 238000004108 freeze drying Methods 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 229960003711 glyceryl trinitrate Drugs 0.000 description 1
- 229910052736 halogen Inorganic materials 0.000 description 1
- OXLZNBCNGJWPRV-UHFFFAOYSA-N hexoprenaline Chemical compound C=1C=C(O)C(O)=CC=1C(O)CNCCCCCCNCC(O)C1=CC=C(O)C(O)=C1 OXLZNBCNGJWPRV-UHFFFAOYSA-N 0.000 description 1
- 229960000708 hexoprenaline Drugs 0.000 description 1
- 239000012456 homogeneous solution Substances 0.000 description 1
- 150000002430 hydrocarbons Chemical class 0.000 description 1
- 229910052739 hydrogen Inorganic materials 0.000 description 1
- 208000030603 inherited susceptibility to asthma Diseases 0.000 description 1
- 229940125396 insulin Drugs 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- 239000004816 latex Substances 0.000 description 1
- 229920000126 latex Polymers 0.000 description 1
- 229960003587 lisuride Drugs 0.000 description 1
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 description 1
- 150000007522 mineralic acids Chemical class 0.000 description 1
- 235000019691 monocalcium phosphate Nutrition 0.000 description 1
- 239000000178 monomer Substances 0.000 description 1
- 229910000402 monopotassium phosphate Inorganic materials 0.000 description 1
- 235000019796 monopotassium phosphate Nutrition 0.000 description 1
- 229910000403 monosodium phosphate Inorganic materials 0.000 description 1
- 235000019799 monosodium phosphate Nutrition 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 235000005152 nicotinamide Nutrition 0.000 description 1
- 239000011570 nicotinamide Substances 0.000 description 1
- 150000007524 organic acids Chemical class 0.000 description 1
- 239000008194 pharmaceutical composition Substances 0.000 description 1
- PJNZPQUBCPKICU-UHFFFAOYSA-N phosphoric acid;potassium Chemical compound [K].OP(O)(O)=O PJNZPQUBCPKICU-UHFFFAOYSA-N 0.000 description 1
- PIJVFDBKTWXHHD-HIFRSBDPSA-N physostigmine Chemical compound C12=CC(OC(=O)NC)=CC=C2N(C)[C@@H]2[C@@]1(C)CCN2C PIJVFDBKTWXHHD-HIFRSBDPSA-N 0.000 description 1
- 229960001697 physostigmine Drugs 0.000 description 1
- 229920000747 poly(lactic acid) Polymers 0.000 description 1
- 229920002239 polyacrylonitrile Polymers 0.000 description 1
- 238000006116 polymerization reaction Methods 0.000 description 1
- 229920002223 polystyrene Polymers 0.000 description 1
- 229920002689 polyvinyl acetate Polymers 0.000 description 1
- 239000011118 polyvinyl acetate Substances 0.000 description 1
- 229920000915 polyvinyl chloride Polymers 0.000 description 1
- 229920001290 polyvinyl ester Polymers 0.000 description 1
- 229920001289 polyvinyl ether Polymers 0.000 description 1
- 229910052700 potassium Inorganic materials 0.000 description 1
- 239000001508 potassium citrate Substances 0.000 description 1
- 229960002635 potassium citrate Drugs 0.000 description 1
- QEEAPRPFLLJWCF-UHFFFAOYSA-K potassium citrate (anhydrous) Chemical compound [K+].[K+].[K+].[O-]C(=O)CC(O)(CC([O-])=O)C([O-])=O QEEAPRPFLLJWCF-UHFFFAOYSA-K 0.000 description 1
- 235000011082 potassium citrates Nutrition 0.000 description 1
- 239000001472 potassium tartrate Substances 0.000 description 1
- 229940111695 potassium tartrate Drugs 0.000 description 1
- 235000011005 potassium tartrates Nutrition 0.000 description 1
- 239000000843 powder Substances 0.000 description 1
- FASDKYOPVNHBLU-ZETCQYMHSA-N pramipexole Chemical compound C1[C@@H](NCCC)CCC2=C1SC(N)=N2 FASDKYOPVNHBLU-ZETCQYMHSA-N 0.000 description 1
- 229960003089 pramipexole Drugs 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000009467 reduction Effects 0.000 description 1
- 230000001105 regulatory effect Effects 0.000 description 1
- 229960002052 salbutamol Drugs 0.000 description 1
- PBGIBLLOMGURPS-GRGSLBFTSA-N semorphone Chemical compound O([C@H]1C(CC[C@]23O)=O)C4=C5[C@@]12CCN(CCOC)[C@@H]3CC5=CC=C4O PBGIBLLOMGURPS-GRGSLBFTSA-N 0.000 description 1
- 230000036556 skin irritation Effects 0.000 description 1
- 231100000475 skin irritation Toxicity 0.000 description 1
- 229910052708 sodium Inorganic materials 0.000 description 1
- 235000015424 sodium Nutrition 0.000 description 1
- HELHAJAZNSDZJO-OLXYHTOASA-L sodium L-tartrate Chemical compound [Na+].[Na+].[O-]C(=O)[C@H](O)[C@@H](O)C([O-])=O HELHAJAZNSDZJO-OLXYHTOASA-L 0.000 description 1
- 239000001632 sodium acetate Substances 0.000 description 1
- 235000017281 sodium acetate Nutrition 0.000 description 1
- 229910000030 sodium bicarbonate Inorganic materials 0.000 description 1
- 235000017557 sodium bicarbonate Nutrition 0.000 description 1
- 235000017550 sodium carbonate Nutrition 0.000 description 1
- 239000001509 sodium citrate Substances 0.000 description 1
- AJPJDKMHJJGVTQ-UHFFFAOYSA-M sodium dihydrogen phosphate Chemical compound [Na+].OP(O)([O-])=O AJPJDKMHJJGVTQ-UHFFFAOYSA-M 0.000 description 1
- 239000001433 sodium tartrate Substances 0.000 description 1
- 229960002167 sodium tartrate Drugs 0.000 description 1
- 235000011004 sodium tartrates Nutrition 0.000 description 1
- 235000010339 sodium tetraborate Nutrition 0.000 description 1
- IZUPJOYPPLEPGM-UHFFFAOYSA-M sodium;hydron;phthalate Chemical compound [Na+].OC(=O)C1=CC=CC=C1C([O-])=O IZUPJOYPPLEPGM-UHFFFAOYSA-M 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000000725 suspension Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 229960001367 tartaric acid Drugs 0.000 description 1
- 229960000195 terbutaline Drugs 0.000 description 1
- BSVBQGMMJUBVOD-UHFFFAOYSA-N trisodium borate Chemical compound [Na+].[Na+].[Na+].[O-]B([O-])[O-] BSVBQGMMJUBVOD-UHFFFAOYSA-N 0.000 description 1
- 229960003726 vasopressin Drugs 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/70—Web, sheet or filament bases ; Films; Fibres of the matrix type containing drug
- A61K9/7023—Transdermal patches and similar drug-containing composite devices, e.g. cataplasms
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61L—METHODS OR APPARATUS FOR STERILISING MATERIALS OR OBJECTS IN GENERAL; DISINFECTION, STERILISATION OR DEODORISATION OF AIR; CHEMICAL ASPECTS OF BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES; MATERIALS FOR BANDAGES, DRESSINGS, ABSORBENT PADS OR SURGICAL ARTICLES
- A61L15/00—Chemical aspects of, or use of materials for, bandages, dressings or absorbent pads
- A61L15/16—Bandages, dressings or absorbent pads for physiological fluids such as urine or blood, e.g. sanitary towels, tampons
- A61L15/42—Use of materials characterised by their function or physical properties
- A61L15/44—Medicaments
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M35/00—Devices for applying media, e.g. remedies, on the human body
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61M—DEVICES FOR INTRODUCING MEDIA INTO, OR ONTO, THE BODY; DEVICES FOR TRANSDUCING BODY MEDIA OR FOR TAKING MEDIA FROM THE BODY; DEVICES FOR PRODUCING OR ENDING SLEEP OR STUPOR
- A61M37/00—Other apparatus for introducing media into the body; Percutany, i.e. introducing medicines into the body by diffusion through the skin
Landscapes
- Health & Medical Sciences (AREA)
- Engineering & Computer Science (AREA)
- Life Sciences & Earth Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Hematology (AREA)
- Heart & Thoracic Surgery (AREA)
- Epidemiology (AREA)
- Anesthesiology (AREA)
- Biomedical Technology (AREA)
- Dermatology (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Medicinal Chemistry (AREA)
- Materials Engineering (AREA)
- Medical Informatics (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Hydrogenated Pyridines (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| DE3939703A DE3939703C2 (de) | 1989-12-01 | 1989-12-01 | Verbesserte transdermale Applikation von pharmakologisch aktiven Verbindungen |
| PCT/EP1990/002052 WO1991007998A1 (fr) | 1989-12-01 | 1990-11-29 | SYSTEME TRANSDERMIQUE AMELIORE D'APPLICATION DE COMPOSES PHARMACOLOGIQUEMENT ACTIFS AVEC UN pH REGLE |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO912985L NO912985L (no) | 1991-07-31 |
| NO912985D0 NO912985D0 (no) | 1991-07-31 |
| NO302156B1 true NO302156B1 (no) | 1998-02-02 |
Family
ID=6394557
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO912985A NO302156B1 (no) | 1989-12-01 | 1991-07-31 | Fremgangsmåte for fremstilling av et transdermalt farmasöytisk system |
Country Status (20)
| Country | Link |
|---|---|
| EP (1) | EP0456792B1 (fr) |
| JP (1) | JPH04506811A (fr) |
| KR (1) | KR0143549B1 (fr) |
| AT (1) | ATE185492T1 (fr) |
| AU (1) | AU637861B2 (fr) |
| CA (1) | CA2046337C (fr) |
| DE (2) | DE3939703C2 (fr) |
| DK (1) | DK0456792T3 (fr) |
| ES (1) | ES2139570T3 (fr) |
| FI (1) | FI107707B (fr) |
| GR (1) | GR3032175T3 (fr) |
| HU (1) | HU206993B (fr) |
| IE (1) | IE904322A1 (fr) |
| IL (1) | IL96506A (fr) |
| NO (1) | NO302156B1 (fr) |
| NZ (1) | NZ236280A (fr) |
| PT (1) | PT96045B (fr) |
| RU (1) | RU1834665C (fr) |
| WO (1) | WO1991007998A1 (fr) |
| ZA (1) | ZA909624B (fr) |
Families Citing this family (5)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6057133A (en) * | 1992-11-24 | 2000-05-02 | G. D. Searle | Multivariant human IL-3 fusion proteins and their recombinant production |
| JP3526887B2 (ja) * | 1993-04-23 | 2004-05-17 | 帝國製薬株式会社 | 消炎鎮痛外用貼付剤 |
| US6395292B2 (en) | 1996-02-02 | 2002-05-28 | Alza Corporation | Sustained delivery of an active agent using an implantable system |
| BR0215068A (pt) | 2001-12-21 | 2004-11-09 | Coloplast As | Dispositivo para cuidar de feridas |
| JP7219623B2 (ja) * | 2018-01-30 | 2023-02-08 | 日東電工株式会社 | 経皮吸収型製剤 |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3598122A (en) * | 1969-04-01 | 1971-08-10 | Alza Corp | Bandage for administering drugs |
| US4756710A (en) * | 1985-04-05 | 1988-07-12 | Merck & Co., Inc. | pH-Mediated drug delivery system |
| US4645502A (en) * | 1985-05-03 | 1987-02-24 | Alza Corporation | Transdermal delivery of highly ionized fat insoluble drugs |
| US4690683A (en) * | 1985-07-02 | 1987-09-01 | Rutgers, The State University Of New Jersey | Transdermal varapamil delivery device |
| US4830856A (en) * | 1987-01-27 | 1989-05-16 | Peppers James M | Chelation product |
| ES2062093T3 (es) * | 1988-08-02 | 1994-12-16 | Ciba Geigy Ag | Emplasto de varias capas. |
| WO1990006120A1 (fr) * | 1988-12-01 | 1990-06-14 | Schering Corporation | Compositions d'administration transdermique d'estradiol |
| DE3843557A1 (de) * | 1988-12-23 | 1990-06-28 | Beiersdorf Ag | Transdermales therapeutisches system zur verabreichung von clenbuterol |
-
1989
- 1989-12-01 DE DE3939703A patent/DE3939703C2/de not_active Expired - Fee Related
-
1990
- 1990-11-29 EP EP90917612A patent/EP0456792B1/fr not_active Expired - Lifetime
- 1990-11-29 ES ES90917612T patent/ES2139570T3/es not_active Expired - Lifetime
- 1990-11-29 DE DE59010885T patent/DE59010885D1/de not_active Expired - Lifetime
- 1990-11-29 AU AU68757/91A patent/AU637861B2/en not_active Expired
- 1990-11-29 AT AT90917612T patent/ATE185492T1/de not_active IP Right Cessation
- 1990-11-29 HU HU912638A patent/HU206993B/hu unknown
- 1990-11-29 KR KR1019910700815A patent/KR0143549B1/ko not_active IP Right Cessation
- 1990-11-29 JP JP3500118A patent/JPH04506811A/ja active Pending
- 1990-11-29 WO PCT/EP1990/002052 patent/WO1991007998A1/fr active IP Right Grant
- 1990-11-29 CA CA002046337A patent/CA2046337C/fr not_active Expired - Lifetime
- 1990-11-29 DK DK90917612T patent/DK0456792T3/da active
- 1990-11-29 NZ NZ236280A patent/NZ236280A/en unknown
- 1990-11-29 IL IL9650690A patent/IL96506A/en not_active IP Right Cessation
- 1990-11-30 IE IE432290A patent/IE904322A1/en not_active IP Right Cessation
- 1990-11-30 PT PT96045A patent/PT96045B/pt not_active IP Right Cessation
- 1990-11-30 ZA ZA909624A patent/ZA909624B/xx unknown
-
1991
- 1991-07-30 RU SU915001146A patent/RU1834665C/ru active
- 1991-07-31 FI FI913645A patent/FI107707B/fi active
- 1991-07-31 NO NO912985A patent/NO302156B1/no not_active IP Right Cessation
-
1999
- 1999-12-17 GR GR990403261T patent/GR3032175T3/el unknown
Also Published As
| Publication number | Publication date |
|---|---|
| WO1991007998A1 (fr) | 1991-06-13 |
| HU206993B (en) | 1993-03-01 |
| DE3939703C2 (de) | 1998-07-02 |
| DK0456792T3 (da) | 2000-04-03 |
| CA2046337C (fr) | 2004-05-25 |
| CA2046337A1 (fr) | 1991-06-02 |
| EP0456792B1 (fr) | 1999-10-13 |
| HUT59615A (en) | 1992-06-29 |
| EP0456792A1 (fr) | 1991-11-21 |
| NO912985L (no) | 1991-07-31 |
| RU1834665C (ru) | 1993-08-15 |
| DE59010885D1 (de) | 1999-11-18 |
| DE3939703A1 (de) | 1991-06-06 |
| GR3032175T3 (en) | 2000-04-27 |
| NZ236280A (en) | 1994-06-27 |
| FI913645A0 (fi) | 1991-07-31 |
| NO912985D0 (no) | 1991-07-31 |
| JPH04506811A (ja) | 1992-11-26 |
| PT96045A (pt) | 1991-09-13 |
| IL96506A0 (en) | 1991-08-16 |
| ATE185492T1 (de) | 1999-10-15 |
| ES2139570T3 (es) | 2000-02-16 |
| HU912638D0 (en) | 1992-01-28 |
| PT96045B (pt) | 1998-01-30 |
| KR920700704A (ko) | 1992-08-10 |
| IE904322A1 (en) | 1991-06-05 |
| ZA909624B (en) | 1992-08-26 |
| IL96506A (en) | 1996-01-19 |
| AU637861B2 (en) | 1993-06-10 |
| AU6875791A (en) | 1991-06-26 |
| KR0143549B1 (ko) | 1998-07-01 |
| FI107707B (fi) | 2001-09-28 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US5462744A (en) | Transdermal system for the administration of pharmacological compounds under pH-controlled conditions | |
| US5613958A (en) | Transdermal delivery systems for the modulated administration of drugs | |
| CA2033113C (fr) | Preparation de gel contenant de l'oestrogene | |
| CA2240349A1 (fr) | Dispositif d'administration de medicament | |
| JPH10182439A (ja) | 皮膚もしくは経皮の治療系のための付着−及び接合剤 | |
| JPH10182440A (ja) | 皮膚もしくは経皮の治療系のための付着−及び接合剤及びその使用 | |
| US5252588A (en) | Percutaneously absorbable crosslinked polyvinylpyrrolidone eperisone or tolperisone preparation | |
| KR101316962B1 (ko) | 니코틴 경피 제제의 제조 방법 | |
| JP2004529890A (ja) | 活性成分としてのニコチンを有する可撓性の著しい皮膚透過性治療系 | |
| NZ254107A (en) | Transdermal therapeutic system comprising 17-beta-estradiol as active substance | |
| Yewale et al. | Polymers in transdermal drug delivery | |
| CZ75797A3 (en) | Transdermal therapeutic system having the form of an adhesive plaster | |
| NO302156B1 (no) | Fremgangsmåte for fremstilling av et transdermalt farmasöytisk system | |
| MXPA04011759A (es) | Emplasto conteniendo fentanilo. | |
| CA2041330C (fr) | Preparation d'eperisone ou de tolperisone a absorption percutanee | |
| KR100549846B1 (ko) | 활성물질 스코폴라민 염기를 함유하는 경피 치료 시스템 | |
| JP4331984B2 (ja) | 医療用経皮吸収テープ製剤用水性エマルジョン粘着剤並びに医療用経皮吸収テープ製剤及びその製造法 | |
| WO1995002404A1 (fr) | Systeme d'apport transdermique de melatonine | |
| CN109394735B (zh) | 具有高溶解度的布洛芬或其结构类似物经皮给药系统 | |
| CA2414753C (fr) | Systeme therapeutique dermique contenant de l'acide 2-(3-benzophenyl)-propionique ou de l'acide [0-(2,6-dichloranilino)-phenyl]-acetique | |
| IL114949A (en) | A multi-layered skin healing system that contains estradiol and a process for its production | |
| JPH07145061A (ja) | 経皮吸収製剤 | |
| JPS5835113A (ja) | 複合製剤 | |
| KR100394830B1 (ko) | 스코폴아민패치 | |
| JP2520960B2 (ja) | 経皮吸収製剤 |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MK1K | Patent expired |